嗜酸粒细胞趋化蛋白-2血清含量对结直肠癌的诊断价值

摘要
图/表
参考文献(0)
相关文章 (15)

全文: PDF (1015 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的:探讨嗜酸粒细胞趋化蛋白-2（eosinophil chemotactic protein 2,eotaxin2）的血清含量对结直肠癌的诊断价值。方法:选取2020年1月至2021年2月在江苏大学附属医院胃肠外科就诊的结直肠癌患者50例作为研究对象,另选取同期健康体检者40例作为对照组。酶联免疫吸附实验（ELISA）检测结直肠癌患者及对照组血清中eotaxin-2的含量。分析血清eotaxin-2含量与结直肠癌患者临床病理参数的相关性。绘制受试者工作特征（ROC）曲线并分析血清eotaxin-2对结直肠癌的筛查效能。结果:结直肠癌患者血清中eotaxin-2的含量明显高于健康对照组（Z=-3.93,P<0.01）；血清eotaxin-2含量与结直肠癌患者淋巴转移、远处转移及TNM分期相关（P均<0.01）,而与患者的性别、年龄、肿瘤类型、瘤体大小无明显关系（P均>0.05）；血清eotaxin2诊断结直肠癌的ROC曲线下面积为0.742（95% CI为0.639~0.845,P<0.01）,诊断敏感性为68.0%,特异性为77.5%。结论:结直肠癌患者血清eotaxin-2含量显著升高,有望成为结直肠癌诊断的生物学标志物。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	徐小卫
	董利阳
	郑婷婷
	刘佳梦
	张珊
	高学荣
	毛朝明

关键词 ：结直肠癌, 肿瘤标志物, 嗜酸粒细胞趋化蛋白-2, 癌胚抗原, 临床病理特征, 趋化因子

Abstract：Objective: To detect the expression of eosinophil chemotactic protein 2 (eotaxin-2) in the serum of patients with colorectal cancer (CRC), and investigate its clinical significance. Methods: A total of 50 CRC patients seeking medical care in the Gastroenterology Department of Affiliated Hospital of Jiangsu University from January 2020 to February 2021 were selected as the CRC group, and 40 healthy subjects in the same period were selected as the healthy controls. The serum eotaxin-2 levels were detected by enzyme-linked immunosorbent assay (ELISA). The association between eotaxin-2 level and the clinicopathological features of CRC was analyzed, and the value of serum eotaxin-2 in the diagnosis of CRC was evaluated by the receiver operating characteristic (ROC) curve. Results: The expression level of serum eotaxin-2 was significantly higher in CRC than that in the healthy controls (Z=-3.93, P<0.01). No significant differences were found among the expression levels of serum eotaxin-2 with respect to the gender, age, lesion location and tumor size (all P>0.05), but was significantly correlated with the lymph-node metastasis, distant metastasis and TNM stage (all P<0.01). The area under the ROC was 0.742 (95% CI: 0.639-0.845, P<0.01). The sensitivity and specificity of serum eotaxin-2 for the diagnosis of CRC were 68.0% and 77.5%, respectively. Conclusion: Serum eotaxin2 level is increased in CRC patients, and may be a candidate biomarker for the CRC diagnosis.

收稿日期: 2021-06-18

基金资助:国家自然科学基金青年科学基金项目（81900562）；镇江市社会发展项目（SH2019047）

通讯作者: 董利阳（通讯作者）,硕士生导师,E-mail:dongliyang0829@hotmail.com

作者简介: 徐小卫（1992—）,男,硕士研究生

引用本文:

徐小卫,董利阳,郑婷婷,刘佳梦,张珊,高学荣,毛朝明. 嗜酸粒细胞趋化蛋白-2血清含量对结直肠癌的诊断价值[J]. 江苏大学学报:医学版, 2022, 22(1): 54-57. XU Xiaowei, DONG Liyang, ZHENG Tingting, LIU Jiameng, ZHANG Shan, GAO Xuerong, MAO Chaoming. Diagnostic value of serum eotaxin-2 in colorectal cancer patients. Journal of Jiangsu University(Medicine Edition), 2022, 22(1): 54-57.

链接本文:

http://zzs.ujs.edu.cn/xbyxb/CN/ 或 http://zzs.ujs.edu.cn/xbyxb/CN/Y2022/V22/I1/54

［1］Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021［J］. CA Cancer J Clin, 2021, 71(1): 7-33.

［2］Worm rntoft MB. Review of bloodbased colorectal cancer screening: How far are circulating cellfree DNA methylation markers from clinical implementation?［J］. Clin Colorectal Cancer, 2018, 17(2): e415-e433.

［3］Chang W, Wu L, Cao F, et al. Development of autoantibody signatures as biomarkers for early detection of colorectal carcinoma［J］. Clin Cancer Res, 2011, 17(17): 5715-5724.

［4］Grothey A, Venook AP. Optimizing adjuvant therapy for localized colon cancer and treatment selection in advanced colorectal cancer［J］. J Natl Compr Canc Netw, 2018, 16(5S): 611-615.

［5］Conlon KC, Miljkovic MD, Waldmann TA. Cytokines in the treatment of cancer［J］. J Interferon Cytokine Res, 2019, 39(1): 6-21.

［6］屠强,彭启松,金洁. 白介素7在结直肠癌患者外周血和癌组织中的表达及其临床意义［J］. 江苏大学学报 (医学版), 2016, 26(5): 437-439.

［7］Korbecki J, Kojder K, Simińska D, et al. CC chemokines in a tumor: A review of procancer and anticancer properties of the ligands of receptors CCR1, CCR2, CCR3, and CCR4［J］. Int J Mol Sci, 2020, 21(21): 8412.

［8］Ahmadi Z, Hassanshahi G, Khorramdelazad H, et al. An overlook to the characteristics and roles played by eotaxin network in the pathophysiology of food allergies: allergic asthma and atopic dermatitis［J］. Inflammation, 2016, 39(3): 1253-1267.

［9］Ablin JN, EntinMeer M, Aloush V, et al. Protective effect of eotaxin2 inhibition in adjuvantinduced arthritis［J］. Clin Exp Immunol, 2010, 161(2): 276-283.

［10］Coleman JM, Naik C, Holguin F, et al. Epithelial eotaxin2 and eotaxin3 expression: relation to asthma severity, luminal eosinophilia and age at onset［J］. Thorax, 2012, 67(12): 1061-1066.

［11］Zajkowska M, Mroczko B. Eotaxins and their receptor in colorectal cancer —A literature review［J］. Cancers (Basel), 2020, 12(6): 1383.

［12］Cheadle EJ, Riyad K, Subar D, et al. Eotaxin2 and colorectal cancer: a potential target for immune therapy［J］. Clin Cancer Res, 2007, 13(19): 5719-5728.

［13］Cho H, Lim SJ, Won KY, et al. Eosinophils in colorectal neoplasms associated with expression of CCL11 and CCL24［J］. J Pathol Transl Med, 2016, 50(1): 45-51.

［14］Tang Z, Kang B, Li C, et al. GEPIA2: an enhanced web server for largescale expression profiling and interactive analysis［J］. Nucleic Acids Res, 2019, 47(W1): W556-W560.

［15］Olsen RS, Nijm J, Andersson RE, et al. Circulating inflammatory factors associated with worse longterm prognosis in colorectal cancer［J］. World J Gastroenterol, 2017, 23(34): 6212-6219.

［16］Gong D, Li Z, Ding R, et al. Extensive serum biomarker analysis in patients with nasopharyngeal carcinoma［J］. Cytokine, 2019, 118: 107-114.

［17］Wang C, Wang Y, Hong T, et al. Blocking the autocrine regulatory loop of Gankyrin/STAT3/CCL24/CCR3 impairs the progression and pazopanib resistance of clear cell renal cell carcinoma［J］. Cell Death Dis, 2020, 11(2): 117.